前收市價 | 12.05 |
開市 | 12.05 |
買盤 | 11.98 x 200 |
賣出價 | 12.10 x 100 |
今日波幅 | 11.89 - 12.44 |
52 週波幅 | 10.87 - 83.60 |
成交量 | |
平均成交量 | 1,293,462 |
市值 | 1.29B |
Beta 值 (5 年,每月) | 0.43 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.95 |
業績公佈日 | 2024年5月02日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 27.33 |
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.
Novocure had good news mixed with some not-so-good news.